A Liver Function Test (LFT) is a group of blood tests used to evaluate liver-related enzymes, proteins, and substances processed or produced by the liver. An LFT commonly includes ALT, AST, ALP, GGT, total bilirubin, direct bilirubin, albumin, and total protein. It may be ordered to investigate symptoms such as jaundice, abdominal discomfort, fatigue, dark urine, or unexplained itching, or to monitor known liver disease and treatment.

Fasting is not always required for an LFT. Requirements depend on the laboratory and whether other tests are being performed at the same time. If your LFT is ordered together with tests that require fasting, such as certain lipid or glucose tests, your healthcare provider may recommend fasting. Follow the specific preparation instructions provided by your laboratory or healthcare professional.

ALT and AST are enzymes that can increase when liver cells are injured. ALT is generally more closely associated with liver injury, while AST can also increase with injury to muscles and other tissues. Elevated results may occur with conditions such as viral hepatitis, fatty liver disease, alcohol-related liver injury, medication effects, or other causes. The degree and pattern of elevation should be interpreted together with the other LFT results and clinical findings.

High bilirubin levels are called hyperbilirubinemia. Increased bilirubin may occur when red blood cells are broken down excessively, when the liver cannot adequately process bilirubin, or when bile flow is impaired. Depending on the cause, elevated bilirubin may be associated with jaundice, dark urine, pale stools, or yellowing of the skin and eyes. Total and direct bilirubin results are interpreted together with other LFT parameters and clinical findings.

Yes. Some prescription medicines, over-the-counter drugs, herbal products, and dietary supplements can affect liver-related blood tests. Certain medications may increase ALT, AST, ALP, or bilirubin, while others may have little or no measurable effect. Do not stop prescribed medication without medical advice. Tell your healthcare provider about all medicines and supplements you are taking so the results can be interpreted appropriately.

LFT results are commonly available within a few hours to one day in many routine laboratories, although turnaround time varies by laboratory, location, and the specific tests requested. Specialized testing or additional investigations may take longer. Your laboratory can provide the expected reporting time for your sample.

Yes. Alcohol consumption can affect several liver-related laboratory results, particularly with repeated or heavy alcohol use. It may contribute to elevations in AST, ALT, and GGT and can affect liver function over time. The effect depends on the amount and pattern of alcohol use and the individual’s underlying health. Tell your healthcare provider about alcohol consumption when discussing abnormal LFT results.

A typical LFT panel may include several enzymes, proteins, and bilirubin measurements:

• ALT: Alanine aminotransferase, a marker of hepatocellular injury
• AST: Aspartate aminotransferase, which can increase with liver or muscle injury
• ALP: Alkaline phosphatase, associated with cholestasis as well as bone and other tissues
• GGT: Gamma-glutamyl transferase, useful in evaluating hepatobiliary enzyme abnormalities
• Total and direct bilirubin: Reflect bilirubin production, processing, and excretion
• Albumin: A major protein synthesized by the liver
• Total protein: Includes albumin and globulins

The exact combination of tests varies between laboratories and clinical situations.

ALT and AST are aminotransferase enzymes released into the blood when cells are injured. ALT is more concentrated in the liver and is therefore generally more liver-specific than AST. AST is also present in skeletal muscle, cardiac muscle, and other tissues. The AST-to-ALT relationship may provide additional clinical information, but it should not be interpreted alone and must be considered with the patient’s history and other laboratory findings.

LFT abnormalities are often classified according to the predominant pattern of enzyme elevation:

• Hepatocellular pattern: Aminotransferases such as ALT and AST are disproportionately elevated compared with ALP.
• Cholestatic pattern: ALP and often GGT are disproportionately elevated compared with ALT and AST.
• Mixed pattern: Both aminotransferases and cholestatic enzymes are significantly elevated.

Pattern recognition helps guide further investigation but does not by itself establish a specific diagnosis.

Total bilirubin represents the overall bilirubin concentration in the blood, while direct bilirubin primarily represents conjugated bilirubin. Indirect bilirubin is generally estimated from the difference between total and direct bilirubin when appropriate. The pattern of bilirubin elevation can help distinguish problems involving bilirubin production, hepatic processing, or bile excretion.

Alkaline phosphatase (ALP) is present in several tissues, especially the liver, bile ducts, and bone. Therefore, an elevated ALP does not automatically indicate liver disease. Physiological increases can also occur during periods of bone growth, and pathological elevations may occur with certain bone disorders. GGT or other clinical findings can help determine whether an elevated ALP is more likely to have a hepatobiliary origin.

Albumin is the major protein synthesized by the liver. A low albumin concentration can occur with reduced hepatic synthetic capacity, but it is not specific for liver disease. Low albumin may also result from malnutrition, inflammation, kidney disease with protein loss, gastrointestinal protein loss, or other conditions. Because albumin has a relatively long half-life, it generally reflects longer-term changes rather than acute liver cell injury.

Reference ranges vary between laboratories because they may use different analytical methods, instruments, populations, and reference interval procedures. Age, sex, pregnancy, and other biological factors can also influence some results. A value outside the laboratory’s reference interval does not automatically indicate disease, while a result within the range does not always exclude disease. Always interpret LFT results using the reference interval printed on the laboratory report and the clinical context.

A hepatocellular pattern is characterized by aminotransferase elevations, particularly ALT and AST, that are disproportionately greater than the increase in ALP. The pattern should be assessed using the degree of elevation relative to each laboratory’s upper limit of normal. Causes include viral hepatitis, metabolic dysfunction-associated steatotic liver disease, alcohol-related liver injury, autoimmune disease, ischemic injury, and drug-induced liver injury. Further interpretation requires clinical history and additional testing.

A cholestatic pattern is characterized by a disproportionate elevation of alkaline phosphatase (ALP), often accompanied by an increase in GGT and sometimes direct bilirubin. Potential causes include intrahepatic cholestasis, biliary obstruction, cholangitis, medication-related cholestasis, and other hepatobiliary disorders. When ALP is elevated, GGT or another appropriate test may help determine whether the source is hepatobiliary rather than bone.

Hyperbilirubinemia can result from several mechanisms:

• Increased bilirubin production: Hemolysis and other causes of increased red blood cell breakdown
• Impaired hepatic uptake or conjugation: Certain inherited disorders and other hepatic conditions
• Hepatocellular dysfunction: Hepatitis and other liver disorders
• Impaired bile excretion: Cholestasis or biliary obstruction

The relative proportions of direct and indirect bilirubin, together with ALT, AST, ALP, GGT, and clinical findings, help determine the likely mechanism.

The R-value (R ratio) compares the patient’s ALT and ALP elevations relative to their respective upper limits of normal. It is commonly used to classify suspected drug-induced liver injury patterns. An R-value of approximately 5 or greater suggests a hepatocellular pattern, approximately 2 or less suggests a cholestatic pattern, and values between these ranges suggest a mixed pattern. The R-value should be interpreted with clinical history, timing, medication exposure, and other laboratory findings.

Several pre-analytical factors can influence liver-related laboratory results:

• Hemolysis: Can interfere with or increase measurement of certain analytes, including AST and other intracellular constituents
• Sample handling: Delayed separation or inappropriate storage may affect some measurements
• Fasting status: May influence selected biochemical measurements depending on the test panel
• Exercise: Strenuous exercise can increase AST and other enzymes associated with muscle injury
• Medications and supplements: May produce genuine biological changes in liver-related results

Modern clinical chemistry analyzers commonly use automated spectrophotometric and enzymatic methods for LFT parameters. Depending on the analyte and analyzer, methods may include kinetic enzyme assays for ALT, AST, ALP, and GGT; diazo or other colorimetric methods for bilirubin; and dye-binding or immunochemical methods for proteins such as albumin. Laboratories validate and monitor these methods using appropriate calibration, internal quality control, and external quality assessment procedures.

Significantly abnormal LFT results should be evaluated according to the pattern, magnitude, symptoms, previous results, and clinical context. Assessment may include review of medications and supplements, alcohol exposure, viral hepatitis risk, metabolic risk factors, and other relevant history. Depending on the findings, clinicians may request repeat testing, additional laboratory studies, imaging, or specialist assessment. Extremely abnormal results accompanied by symptoms such as jaundice, confusion, severe abdominal pain, bleeding, or marked illness require prompt medical evaluation.

Quality assurance for LFT testing includes calibration verification, internal quality control, reagent monitoring, instrument maintenance, analytical performance verification, and external quality assessment. Laboratories should monitor precision and accuracy for relevant analytes and investigate control failures before reporting patient results. Pre-analytical specimen quality, reagent lot changes, calibration status, and analyzer performance should also be monitored according to the laboratory’s quality management system.